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esponsibility of InstAbstract Interferon (IFN) in combination with ribavirin has been the standard of care (SOC) for chronic
hepatitis C for the past few decades. Although the current SOC lacks the desired efﬁcacy, and 4 new
direct-acting antiviral agents have been recently approved, interferons are still likely to remain the
cornerstone of therapy for some time. Moreover, as an important cytokine system of innate immunity, host
interferon signaling provides a powerful antiviral response. Nevertheless, the mechanisms by which HCV
infection controls interferon production, and how interferons, in turn, trigger anti-HCV activities as well
as control the outcome of HCV infection remain to be clariﬁed. In this report, we review current progress0
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interferon signaling by HCV infection.
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Interferons (IFNs) are a family of cytokines secreted by host cells in
response to various pathogens like viruses, bacteria, fungi, or parasites
which trigger the protective defenses of the immune system1. To
defend against invading viral pathogens, the interferon signatures
activate the transcription of numerous IFN-stimulated genes (ISGs)
and thus promote a broad-spectrum of antiviral responses2.
In 1986, interferon-α (IFN-α) was ﬁrst approved as a treatment
for patients with non-A non-B (now renamed type C) chronic
hepatitis. After this landmark study, further improvements in
research technologies led to increased sustained virological
response (SVR) rates. These included addition of the guanosine
analog ribavirin to IFN treatment3, followed by pegylation of the
IFN molecule. Pegylated IFN-α, which was developed to extend
the interdose interval to at least one week, offered improved
convenience, decreased side effects, and superior clinical efﬁcacy
when compared with IFN-α. Presently, the standard treatment of
chronic hepatitis C remains the combination of pegylated IFN-α
and RBV. Recently, three NS3-4A protease inhibitors, telaprevir
(Vertex/Janssen)4, boceprevir (Merck) and simeprevir (Janssen)5,6,
and one NS5B RNA dependent RNA polymerase (RdRp) inhibitor
sofosbuvir (Gilead)6, have been approved in combination with
pegylated IFN-α and ribavirin for the treatment of chronic HCV
infection. These agents will improve the rate of SVR, but their
toxicities combined with Pegylated IFN-α and RBV may limit
their overall efﬁcacy. For this reason, interferons are still likely to
remain the cornerstone of therapy for some time.
Since the ﬁrst use of the standard therapeutic paradigm against
chronic hepatitis C more than 20 years ago, fundamental biome-
dical research has greatly improved our understanding of the
underlying molecular mechanisms of IFN production, regulation
and antiviral action. This has been accompanied by substantial
progress in understanding the HCV life cycle.
Presently, we review the current information on the mechanisms
of IFN actions against HCV, and summarize the latest knowledge
of induction of interferon signal by HCV infection (Fig. 1).2. Induction of interferon
It is well known that the innate immune response is the ﬁrst line of
defense against viral infections, and IFNs are the central cytokines
responsible for the induction, activation and regulation of the antiviral
state in innate immune cells like natural killer cells (NKCs)7. Based
on their structural features, receptor usage and biological activities,
three distinct types of IFNs are now recognized. Type I IFNs (IFN-α,
IFN-β and IFN-ω) and type III IFNs (IFN-λ1, IFN-λ2 and IFN-λ3;
also named as IL29, IL28A, and IL28B respectively) are produced by
most types of cells which are infected with virus and also by key
sentinel cells of the innate immune system: macrophages and
dendritic cells (DCs). However, the type II IFNs (IFN-γ) are only
produced by certain cells of the immune system, including NKCs andnatural killer T cells (NKTCs), which belong to a part of the innate
immune response, as well as antigen-speciﬁc T cells (both CD4þ T
helper 1 and CD8þ cytotoxic T cells).
It is now clear that there are several families of pattern recognition
receptors (PRRs) surveying the cellular micro-environment for viral
infection. The two important characterized families of PRRs that
detect viral genomes and then induce type I and type III IFNs are the
Toll-like receptors (TLRs) and the retinoic acid-inducible gene-I
(RIG-I)8. After recognizing viral infection, these receptors initiate
intracellular signaling cascades, which are responsible for the
production of type I and type III IFNs and proinﬂammatory
cytokines, and mediate the antiviral immune response ﬁnally. TLRs
are a family of transmembrane pattern recognition receptors that
recognize microbial pathogen-associated molecular patterns (PAMPs)
and activate the expression of genes involved in inﬂammatory and
immune responses9. There are at least 10 human TLRs, and 5 of them
are involved in the recognition of viral infections. TLR3, TLR7 and
TLR9 represent a TLR subfamily that recognize viral nucleic acids
and induce an endogenous interferon response, while viral glycopro-
teins have been shown to interact with TLR2 and TLR4. TLRs are
expressed on several types of immune cells including macrophages,
DCs, B cells, as well as ﬁbroblasts and epithelial cells. When the
HCV invades, the TLR2 will recruit TLR1 and TLR6 as coreceptors
for HCV core- and NS3-mediated activation of macrophages and
innate immunity in humans10. Meanwhile, HCV infection directly
induces TLR4 expression and thereby activates B cells, which may
contribute to the host's innate immune responses11. Along with
TLR3, TLR7 and TLR9 are localized in intracellular compartments
such as endosomes. The latest reports show that TLR3 and TLR7
play highly signiﬁcant roles in the recognition of HCV RNA12–15;
TLR3 senses double-stranded RNA (dsRNA), which is an essential
intermediate in the HCV replication cycle, and then initiates signaling
that activates NF-κB and interferon regulatory factor 3 (IRF-3),
thereby inducing the synthesis of type I IFN16. TLR7, expressed on
the DCs and Kupffer cells, shows a very good ability to sense the
HCV RNA, subsequently leading to the synthesis of type I IFNs12,17.
Importantly, macrophages and DCs do not have to directly infect
themselves by HCV in order to produce IFNs. Instead, they
constantly screen materials from the outside, including intact viral
particles and cellular remnants containing viral fractions. After the
degradation in the endosomes, viral nucleic acids are exposed and
recognized by TLRs. In addition, viruses escaping the endosomal
entry pathway can be detected by the cytosolic pathways and then
induce types I and III IFNs. In general, viral RNA genomes or viral
replication intermediates can be sensed in cytoplasm or endosomes by
the related cytoplasmic RNA helicases RIG-I and melanoma
differentiation-associated gene-5 (MDA-5). Accumulating evidence
suggests that RIG-I-like receptors (RLRs), particularly RIG-I and
MDA5, are responsible for the recognition of HCV RNA18. It has
been reported that RIG-I senses HCV RNA in the early stage of
infection and activates downstream pathways of the innate immune
response19. After sensing the viral RNA, these sensors utilize the
mitochondrial antiviral signaling protein (MAVS, also known as
Figure 1 Pathways of interferon induction and effect in HCV infection. HCV RNA leads to the transcription of interferon genes through TLR3 in
endosome and/or RIG-I in cytoplasm. Type I IFNs and type III IFNs bind to respective receptors, activate the same JAK-STAT pathway and then
induce the overlapping ISGs. IFN-γ activates STAT1 and induces a partially overlapping but distinct ISGs. As the members of ISGs, PKR and/or
OAS/RNaseL pathways play important roles in the anti-HCV action.
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cascades. MAVS then propagates the signal to the closely related
kinases TBK1 and IKKε, or the IKKα and IKKβ kinases. These
kinases phosphorylate and thus activate the critical transcription
factors IRF-3 and IRF-7 respectively, which bind to the response
elements, eventually promoting expression of types I and III IFNs'
genes21.
All types of IFNs induce an antiviral micro-environment in host
cells by the transcriptional activation of hundreds of genes. The
speciﬁc set of genes differs among IFNs and target cell types. In
general, type I and type III IFNs induce a largely overlapping set
of genes in cells22, whereas the gene set induced by type II IFNs is
more distinct23. Meanwhile, the number of genes regulated by
IFNs also differs among cell types. For instance, pegylated IFN-α
induces 200–300 genes in liver cells, but nearly 2000 genes in
peripheral blood mononuclear cells (PBMCs)24.3. Anti-HCV mechanism of interferons
3.1. Anti-HCV mechanisms of type I interferon
Type I interferons belong to a family of major innate immune
cytokines produced by host cells in response to viral infections. Since
their discovery, their antiviral actions have been studied extensively,
leading to the development of the ﬁrst cytokine-based therapy. This
treatment is licensed worldwide for several viral diseases, malignancies,and even immune disorders25,26. Type I IFNs bind a unique ubiquitous
heterodimeric receptor consisting of interferon-alpha receptor 1/2
(IFNAR1/IFNAR2), leading to the activation of signaling pathways
and the subsequent induction of a large number of ISGs. ISG-encoded
proteins mediate the antiviral and other effects of interferons27. The
downstream signaling pathways for these receptors have been exten-
sively described: IFNAR1 and IFNAR2 are associated with the Janus
activated kinases (JAKs) tyrosine kinase 2 (TYK2) and JAK1,
respectively. Binding of type I IFNs to their heterodimeric receptors
leads to activation of JAKs, which results in tyrosine phosphorylation
of signal transducer and activator of transcription 2 (STAT2) and
STAT1; STAT1/STAT2 migrates into the nucleus and associates with
the IFN regulatory factor 9 (IRF9), to form the STAT1–STAT2–IRF9
complex (also known as IFN-stimulated gene factor 3 [ISGF3]). This
complex then binds IFN-stimulated response elements (ISREs) inside
DNA to initiate the transcription of hundreds of different ISGs, which
are known to mediate the diverse cellular effects in the infected cell28.
Collectively, these genes facilitate both clearance of virus from infected
cells and protection of neighboring uninfected cells from incoming
viral progeny. The past 50 years of IFN research resulted in
identiﬁcation of a number of key IFN regulatory genes (IRGs). Most
notably, the antiviral-associated proteins 20-50-oligoadenylate synthetase
(OAS) and protein kinase R (PKR) have been intensely studied to
understand their roles in the antiviral effects regulated through IFN
signaling. Among the genes induced by type I IFNs, perhaps the most
intensely studied is PKR. This kinase plays an important role in the
antiviral response through phosphorylation of elF2α and inhibition of
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et al.29 showed that the host cell can employ PKR activation to restrict
HCV 1a replication through regulating the NF-κB pathway. Moreover,
the IFN-inducible OAS/RNase L pathway blocks multiple viral
infections through cleaving the viral and cellular single-stranded
RNA30. Type I IFNs induced by HCV infection initiate signaling via
the OAS genes; both OAS and RNaseL are implicated in the antiviral
response against hepatitis C virus. Some scientists have suggested that,
among the members of the OAS family, OAS1 p46 and OAS3 p100
mediate the RNaseL-dependent antiviral activity against HCV31. It is
very interesting that RNase L and PKR are effectors of the interferon
antiviral response that share homology in their pseudokinase and
protein kinase domains. Very recent research showed that the anti-
cancer drug sunitinib, a potent inhibitor of both RNase L and PKR in
cell cultures as well as in mice, eventually prevented antiviral innate
immune responses mediated by RNase L and PKR32. Sunitinib is
thought to modulate IRE1, an endoplasmic reticulum protein involved
in the unfolded protein response that is closely related to RNase L. In
addition to its direct antiviral actions, IFN has important interactions
with the adaptive and innate immune responses. For example, type I
IFNs can promote memory T-cell proliferation, prevent T-cell apop-
tosis and stimulate NKC activation and DC maturation as well. They
can also up-regulate the production of major histocompatibility
complex (MHC) class-I and class-II peptides, and might promote a
T-helper-1 (TH1) over a T-helper-2 (TH2) phenotype. In addition to its
direct immune-stimulating mechanisms (by decreasing HCV RNA
replication), IFN might prevent immune exhaustion and enhance the
adaptive HCV-speciﬁc immune response33.
In HCV infection, the type I IFN signaling pathway is controlled by
a number of negative signatures; the interferon-stimulated gene 15/
ubiquitin speciﬁc peptidase 18 (ISG15/USP18) pathway belongs to one
of them. The role of ISG15/USP18 pathway in the host innate immune
response is complex. Many studies have suggested that this pathway
provides an important protective role against several viruses34,35.
However, HCV seems to utilize the pathway to enhance its replication
inversely. By utilizing microarray-expression proﬁling, Chen et al.36
identiﬁed three genes, ISG15, USP18 and HERC5, which represent
members of the ubiquitously IFN-regulated ISG15 group, out of a core
set of 18 genes thought to be predictive of this response. Initially, these
authors hypothesized that ISG15/ISGylation was antiviral, and sup-
posed that silencing the USP18 would lead to increasing of ISGylation
and potentiating the anti-viral effect of exogenous IFN-α37. However,
increasing ISGylation independent of USP18 actually promoted
efﬁcient viral replication, such that increasing the level USP18 blunted
the anti-viral effects of IFN-α, promoting HCV production in a
protease-independent fashion38. Based on the above ﬁndings, the
authors concluded that ISGylation promotes HCV production,
decreases the anti-HCV effects of IFN-α and functions in the down-
stream steps of HCV RNA replication. ISG15, however, is generally
considered to be antiviral. Furthermore, the authors pointed out that
ISG15 is a novel mechanism for virus persistence, and ISGylation is a
possible target for therapy of HCV infection38.3.2. The anti-HCV mechanisms of type II interferon
Unlike the types I and III interferon, type II interferon (IFN-γ) is
secreted predominantly by T cells, NKCs and other cells such as
macrophage, DCs, and B cells. In the host, IFN-γ always
stimulates cell-mediated immune responses that are critical for
the development of host protection against pathogenic intracellular
microorganisms. The IFN-γ receptor, widely expressed in hostcells, is composed of two subunits, interferon gamma receptors 1
and 2 (IFNGR1 and IFNGR2, respectively). Each receptor subunit
interacts with a member of the JAK family. Unlike the type I IFN
receptor, IFNGR1 associates with JAK1, and IFNGR2 is asso-
ciated with JAK2. After IFN-γ binds to the type II IFN receptor,
JAK1 and JAK2 are activated and subsequently phosphorylate
only STAT1. Phosphorylated STAT1 self associates to form
homodimers that translocate to the nucleus and where they bind
the IFN-γ-activated site (GAS) elements. The GAS elements
are present in the promoter regions of IFN-γ-regulated genes21,39.
IFN-γ is structurally unrelated to type I and type III IFNs, which
binds to a different receptor encoded by separate chromosomal
locus. However, there are remarkable overlaps in the many
hundreds of genes regulated by both of them40.
There is no convincing evidence that HCV infection can induce
IFN-γ release from NKCs directly. However, some studies show
that type I IFN can increase NKC cytotoxicity directed toward the
HCV infected cells41,42. Although previous reports suggested that
NKCs do not directly respond to HCV virions secreted from HCV-
infected cells43, a recent study reported that NKCs produce IFN-γ
in response to HCV infected cells in a plasmacytoid dendritic cell
(pDC)-and type I IFN-dependent manner. Monocyte-derived IL-15
can augment this process44. Another report demonstrates that
IFN-α activates NKCs in a DNAX accessory molecule-1
(DNAM1)-dependent manner; this leads to efﬁcient recognition
of HCV-infected hepatoma cells and secretion of IFN-γ by
NKCs45. Furthermore, Jia et al.46 reported that IFN-γ has
synergistic antiviral effects with IFN-α.
Importantly, IFN-γ has been demonstrated to be a key cytokine
for clearance of acute and chronic HCV infection47,48. Using gene
transfer technology to produce sustained IFN-γ in the human
hepatocyte chimeric mice infected with genotype 1b HCV,
Takahashi et al. showed that injection of the human IFN-γ-
expressing plasmid vector pCpG-huIFNγ could produce long-
term elimination of HCV RNA in chimeric mice49. As compared
with the cytotoxicity of NKCs, the toxicity of IFN-γ secreted from
NKCs is considered to be a more efﬁcient mechanism against
HCV. The former requires a 1:1 interaction between NKCs and
infected cells, whereas IFN-γ molecules secreted by an individual
NKC may reach hundreds of hepatocytes50.
As mentioned above, the USP18 may participate in the inhibition of
IFN-α signatures, but it does not seem to impact IFN-γ or IFN-λ
signaling 51. One previous study has shown that the HCV envelop 2
(E2) glycoprotein may impair IFN-γ production by NKCs for its
binding to the tetraspanin CD81 on the cell surface52. However, there
are some controversial results. One of study suggests that it is HCV E1
but not E2 which is responsible for modulation of the antiviral function
of NKCs43. Although activated NKCs can recognize and kill hepatoma
cells containing HCV replicon53, there is another suggestion that
cellular contact with hepatoma cells may impair the killing capabilities
and IFN-γ response of NKCs54. The underlying mechanisms leading to
such differences are not entirely clear, and considerable additional
research is needed.3.3. Anti-HCV mechanisms of type III interferon
Two research teams independently claimed the discovery and
initial description of type III interferon (IFN-λ) in 2003, opening a
brand new area of IFN research55,56. Presently 3 different IFN-λ
genes are known to encode 3 distinct but closely related proteins.
These are designated as IFN-λ1, -λ2 and -λ3 or interleukin-29
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interferon, it is clearly structurally related to members of the IL-10
family57. Meanwhile, the IFN-λ genes phylogenetically reside
somewhere between the type I IFN and IL-10 gene families.
Amino acid sequence comparisons show that the type III IFNs
exhibit about 5%–18% homology with either type I IFNs or the
IL-10-related cytokines. Therefore, it is not surprising that the
antiviral activity of type III IFN resembles that of type I IFN.
Similar to type I IFN, the three IFNλs can be triggered by viral
infection, then induce anti-viral and anti-tumor activities through
both innate and adaptive immune system pathways58,59. And yet,
the IFN-λ proteins bind to and signal through a distinct receptor
complex composed of the unique IFN-λR1 chain (also known as
IL-28RA) and interleukin-10 receptor 2 (IL-10R2) receptor chain
(also a part of the receptor complexes for IL-10, IL-22, and IL-
26)60. Moreover, IL-10R2 is only expressed on a few restricted
cell types, including hepatocytes, epithelial cells and pDCs61,62.
Although the receptor complex of IFN-λ is different from that of
type I IFN, signaling through either IFN-λ or IFN-α receptor
complexes results in the activation of the same JAK-STAT signal
transduction cascades63, and result in activation of overlapping
sets of ISGs64. Consequently, the biological activities induced by
type III IFNs are very similar to those induced by type I, including
induction of antiviral activity and up-regulation of MHC class I
antigen expression on many cell types.
As described above, the IFN-λ signal transduction cascades are
very similar to those induced by type I IFNs, so the mechanisms of
HCV inhibition are likely to be the same between the types I and
III IFNs. However, some differences between them are known. For
example, the relative level of gene expression induced by IFN-λ is
always weaker than that induced by IFN-α in many cell types64.
Meanwhile, another study showed that IFN-α triggers an early
peak in ISG expression, which is much greater than that produced
by IFN-λ, followed by a rapid decline22. Furthermore, it has been
suggested that the lower but sustained anti-HCV activity of IFN-λ
could be preferable, since IFN-based therapies are administered
over a relatively long period62.
Convincing evidence supports the suggestion that IFN-λs control
HCV replication through the innate immune pathway22. Moreover,
combinations of IFN-λ1 and IFN-α had a greater inhibitory effect on
HCV replication as compared with the individual agents65. Interest-
ingly, based on the important differences in time-dependent antiviral
responses and ISGs' up-regulation between type I and type III IFN, the
latest research found that a combination of IFN-α and IFN-λ3 produced
synergistic anti-HCV activity66.
Three genome-wide association studies (GWAS) in 2009 identi-
ﬁed three variant genes which strongly associated with both
spontaneous HCV clearance and SVR to pegIFN-α/RBV treatment
for chronic hepatitis C67–69. These gene variants, identiﬁed as
rs12979860, rs12980275 and rs8099917, are single-nucleotide poly-
morphisms (SNPs) on chromosome 19q13.13 near the IFNL3 gene
(IL28B)67–69. Additionally, the patients with these variants were more
likely to spontaneously resolve acute HCV infection without treat-
ment70. Recently, one group has identiﬁed a new inducible human
protein-coding gene, IFN-λ 4 (IFNL4). The polymorphism of IFNL4
was shown to be in high linkage disequilibrium with that of genes
close to IL28B, and more strongly associated with spontaneous or
treatment-induced HCV clearance than IL28B genotypes, especially
in individuals of African ancestry71. These results could provide a
new and rational dimension for HCV research, including more basic
studies on IFN-λs. Furthermore, they suggest the potential for more
personalized novel, effective therapies for HCV infections.4. Conclusions
Modern studies of the induction and biological activity of
interferon in HCV infections have not only promoted our under-
standing of the pathogenesis of the most important liver disease
worldwide, but also made important contributions to uncover the
mysteries of virus–host interactions. The interferon system pro-
vides a powerful antiviral response, which inhibits the replication
of several viruses including HCV, stimulates apoptosis of infected
cells, and modulates the immune system as well. Although much
has been learned about the biological activities of interferon, our
understanding is far from complete. For example, how does HCV
escape from the host immune system and what are the relevant
molecular mechanisms? How can we provide more personalized
chronic hepatitis C (CHC) treatment based on interferon therapy in
the future? Why does interferon treatment fail to control CHC in
some patients, even if there is a very high level of endogenous
interferon? Moreover, what are the underlying molecular mechan-
isms of synergistic anti-HCV activity involving combinations of
different IFNs? Future research is needed to address these
important questions. Gaining new insights into IFNs' anti-HCV
activities, increases in understanding how HCV infection leads to
the induction of interferon signaling are essential for progress in
understanding and treating HCV. Further research is imperative to
develop novel highly effective, personalized treatments for this
devastating liver disease.Acknowledgments
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